Asked by: Craig Tracey (Conservative - North Warwickshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether her Department has made a recent assessment of the potential merits of using breast density assessment software at women's first breast cancer screening appointments; and if she will make an assessment of the potential impact of that technology on women's awareness of their personal risk of developing breast cancer.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The Breast Screening Risk Adaptive Imaging for Density trial is looking into the use of supplementary imaging techniques for women, within the standard breast screening programme, who are found to have radiographically dense breast tissue. The UK National Screening Committee, which advises ministers and the National Health Service in all four countries in the United Kingdom, will review this evidence when it becomes available.
Asked by: Craig Tracey (Conservative - North Warwickshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if she will make an assessment of the potential impact of the decision by the National Institute for Health and Care Excellence to not recommend trastuzumab deruxtecan for HER2-low secondary breast cancer for use on NHS on the life expectancy of eligible women.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The National Institute for Health and Care Excellence (NICE) has not yet published final guidance on the use of trastuzumab deruxtecan (Enhertu) for the treatment of metastatic HER2-low breast cancer. The NICE published final draft guidance on 5 March 2024, that does not recommend it as a clinically and cost-effective use of National Health Service resources. Stakeholders had until 19 March 2024 to lodge an appeal against the NICE’s recommendations. The NICE currently expects to publish final guidance on 3 April 2024.